Highlight
This prespecified exploratory analysis estimated the cardiovascular benefits of tirzepatide by indirectly comparing it to placebo using data from the SURPASS-Cardiovascular Outcomes Trial (SURPASS-CVOT) and the REWIND trial.
The analysis demonstrated a significant reduction in major adverse cardiovascular events (MACE-3), cardiovascular death or heart failure events, and all-cause mortality with tirzepatide compared with imputed placebo.
Propensity score adjustment and multiple sensitivity analyses confirmed consistency and robustness of the findings across different population subsets and analytical models.
No direct placebo-controlled cardiovascular outcomes trial exists for tirzepatide, making this novel imputed placebo approach valuable for understanding its true cardiovascular impact.
